Description

Arrowhead Pharmaceuticals: Precision RNA Interference Meets Neurology—A Platform Strategy Scaling Into CNS!

Arrowhead Pharmaceuticals recently presented their fiscal 2026 first-quarter results, marked by significant developments across various aspects of the business. Among the highlights was the FDA approval of REDEMPLO for familial chylomicronemia syndrome (FCS), alongside approvals from Health Canada and the Chinese National Medical Products Administration. This positions Arrowhead as a commercial entity marketing its own medicines, notably entering the market with REDEMPLO in the U.S. Despite only 10 weeks of sales, the launch showed encouraging trends, receiving over 100 prescriptions from a diverse range of healthcare providers. Arrowhead has set a unified price for REDEMPLO across indications, emphasizing sustainable drug pricing based on value for patients and healthcare systems. They’re committed to providing sufficient access while focusing on patient populations most at risk for triglyceride-related pancreatitis.